PRX004

ESC 2022 – Novo’s cardiovascular charge continues
EP Vantage
Thu, 09/1/22 - 10:13 am
ESC 2022
Novo Nordisk
ziltivekimab
PRX004
HS-001
Novo Nordisk puts $1.2B on the table for Prothena’s ATTR drug, teeing up Alnylam challenge and cardiovascular expansion
Fierce Biotech
Mon, 07/12/21 - 10:40 am
Novo Nordisk
Prothena
ATTR amyloidosis
PRX004